Imatinib mesylate—gold standards and silver linings

@article{Peggs2004ImatinibMS,
  title={Imatinib mesylate—gold standards and silver linings},
  author={Karl S. Peggs},
  journal={Clinical and Experimental Medicine},
  year={2004},
  volume={4},
  pages={1-9}
}
Imatinib mesylate represents the first of a new generation of molecularly targeted therapies engineered to disrupt signal transduction pathways. It is a tyrosine kinase inhibitor with relatively selective activity against the Abelson (ABL) proto-oncogene, platelet-derived growth factor receptor, and c-KIT receptor. Deregulated tyrosine kinase activity has been implicated as a central pathogenic event in a number of human malignancies, most notably chronic myeloid leukemia. In this… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 40 references

( Ph + ALL )

  • S Lee, DW Kim, YJ Kim, NG Chung, YL Kim, JY Hwang
  • 2003

Similar Papers

Loading similar papers…